[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597511":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":45,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":19,"enrollmentInfo":64,"targetDuration":19,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":77,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Anal HPV testing","All included women will leave an anal HPV-self test",[12],"Diagnostic Test: anal HPV screening",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","anal HPV screening","From all included women samples will be collected at the out-patient HIV departments including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Christina Carlander","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+46708830761","christina.carlander@ki.se",[30],{"facility":5,"status":19,"city":31,"state":19,"zip":19,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Stockholm","Sweden","SE",{"type":35,"coordinates":36},"Point",[37,38],18.06871,59.32938,{"lat":38,"lon":37},[41],{"name":42,"role":26,"phone":19,"phoneExt":19,"email":28},"Christina Carlander, MD, PhD",{"type":23,"investigatorFullName":22,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PI",[46,48,50,52],{"name":47,"class":6},"Karolinska University Hospital",{"name":49,"class":6},"Stockholm South General Hospital",{"name":51,"class":6},"Sahlgrenska University Hospital",{"name":53,"class":54},"The Swedish Research Council","OTHER_GOV","100597511","screening-for-anal-cancer-and-precancer-in-women-with-hiv-sanca-100597511",false,"NCT07059442","Screening for Anal Cancer and Precancer in Women With HIV (SANCA)","SANCA","Inclusion Criteria:\n\n* Women (biological sex) with HIV\n* 45 years old or older\n* attending the out-patient HIV departments at Karolinska University Hospital in Stockholm, the South Hospital in Stockholm, and Sahlgrenska University Hospital in Gothenburg\n\nExclusion Criteria:\n\n* Women who have had anal cancer\n* women who have had rectal amputation","FEMALE","45 Years",{"count":65,"type":66},1000,"ESTIMATED","INTERVENTIONAL",[69],"NA","The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.\n\nSecondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries.",[72],"Anal Canal Cancer",[74,75,76],"HIV","Human papilloma virus","DNA methylation","NOT_YET_RECRUITING","2025-07-09",{"date":80,"type":81},"2025-07-10","ACTUAL",{"date":83,"type":66},"2025-09-01",{"date":85,"type":66},"2035-12-31",{"name":5,"class":6},1]